To study the effects of agonist desensitization on channel activation, the extracellular solution contained (in mM): 127 NaCl, 3 KCl, 1 MgCl
2, 10 HEPES, 2.5 CaCl
2 and 10 glucose, pH 7.4 with NaOH. Osmolarity was adjusted to 310 mOsm/l with glucose. The intracellular solution contained (in mM): 135 KCl, 2 MgCl
2, 2 MgATP, 5 EGTA and 10 HEPES, pH 7.4 with CsOH. Osmolarity was adjusted to 300 mOsm/l with glucose.
31 (link)To study the effects of intracellular calcium in channel modulation, the extracellular solution contained (in mM): 140 NaCl, 4 KCl, 2 CaCl
2, 1 MgCl
2, 10 HEPES, pH 7.4 with NaOH. Osmolarity was adjusted to 310 mOsm/l with glucose. The intracellular solution contained (in mM): 130 KCl, 8 NaCl, 2 EGTA, 1 MgCl
2, 1 CaCl
2, 4 MgATP, 0.4 Na2GTP, pH 7.4 with CsOH. Osmolarity was adjusted 300 mOsm/l with glucose.
To investigate voltage dependence, currents were recorded during a voltage-step protocol consisting of 400 ms voltage steps to test potentials ranging from −100 to +180 mV, followed by a final invariant step to −75 mV (400 ms) to measure tail currents. The holding potential was set at −0 mV.
The voltage-dependence activation of hTRPA1 p.Ala172Val in response to mustard oil [Allyl isothiocyanate (AITC) a TRPA1 electrophilic agonist] and Menthol (non-electrophilic agonist of TRPA1) was measured. These recordings were performed in a calcium-containing extracellular solution, to preserve agonist desensitization properties.
33 (link) Perfusion with TRPA1 agonists was performed through a custom-made gravity perfusion system. Immediately after establishing the whole-cell configuration, perfusion was switched to extracellular solution for 2 min before beginning the voltage clamp recording. AITC (Sigma 377430) was dissolved in DMSO (Sigma D2650), and Menthol (Sigma M2772) in ethanol. The maximum final concentration of either DMSO or ethanol did not exceed 0.1%. The effect of TRPA1 agonists on current–voltage curves was measured with a two-voltage-step protocol, as described above. Voltage ramps ranging from −100 to +100 mV for 500 ms, every 5 s, were applied to elucidate the temporal activation of hTRPA1 p.Ala172Val in response to AITC. In this case, the holding potential was set at −70 mV.
Current–voltage curves (
I–
V curves) were fitted using a combined Boltzmann and linear ohmic relationship:
I/
Imax =
Gmax (
Vm−
Erev)/(1 + exp
(V1/2−Vm)/k). Normalized conductance–voltage curves (activation curves) were fitted with a Boltzmann equation
G/
Gmax = 1/(1 + exp
(V1/2−Vm)/K), where
G was calculated as follows
G =
I/(
Vm−
Erev). Steady-state fast inactivation curves were fitted with
IT/
ITmax = 1/(1 + exp
−(V1/2−Vm)/k). Tail current-derived voltage-activation curves were fitted to the Boltzmann equation:
IT/
IT (Max) = 1/(1 + exp
[(Vm−V1⁄2)/k]). In all the equations,
V1/2 represents the half-activation and half-inactivation membrane potentials;
Vm is the membrane potential,
Erev the reversal potential,
k the slope factor,
G the conductance and
IT the current at a given
Vm;
Gmax and
ITmax are the maximum conductance and current, respectively;
Rin is the fraction of channels that are resistant to slow inactivation. Statistical significance was set at
P = 0.05 for group comparisons.
Themistocleous A.C., Baskozos G., Blesneac I., Comini M., Megy K., Chong S., Deevi S.V., Ginsberg L., Gosal D., Hadden R.D., Horvath R., Mahdi-Rogers M., Manzur A., Mapeta R., Marshall A., Matthews E., McCarthy M.I., Reilly M.M., Renton T., Rice A.S., Vale T.A., van Zuydam N., Walker S.M., Woods C.G, & Bennett D.L. (2023). Investigating genotype–phenotype relationship of extreme neuropathic pain disorders in a UK national cohort. Brain Communications, 5(2), fcad037.